Allouche Cyril

CIK 00017445731 companyNEWARK, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001744573

Recent Transactions

18 trades

Sale
Revance Therapeutics, Inc.
Common Stock
2019-03-18$15.48/sh−498→ 6,400 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2019-03-15$15.45/sh−252→ 6,898 total
Award
Revance Therapeutics, Inc.
Common Stock
2019-01-24+3,150→ 7,150 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2019-01-24+6,500→ 6,500 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2019-01-22$13.35/sh+625→ 4,625 total
Sale
Revance Therapeutics, Inc.
Common Stock
2019-01-22$17.77/sh−625→ 4,000 total
Exercise/Conversion
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2019-01-22−625→ 6,875 total
Sale
Revance Therapeutics, Inc.
Common Stock
2019-01-03$19.48/sh−375→ 4,000 total
Other
Revance Therapeutics, Inc.
Common Stock
2018-12-31$17.11/sh+375→ 4,375 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-11-20$20.66/sh−491→ 4,000 total
Tax Payment
Revance Therapeutics, Inc.
Common Stock
2018-11-15$20.99/sh−259→ 4,491 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-11-09$23.72/sh−2,188→ 4,750 total
Exercise/Conversion
Revance Therapeutics, Inc.
Common Stock
2018-11-09$13.35/sh+2,188→ 6,938 total
Exercise/Conversion
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2018-11-09−2,188→ 7,500 total
Sale
Revance Therapeutics, Inc.
Common Stock
2018-07-06$28.35/sh−393→ 4,750 total
Other
Revance Therapeutics, Inc.
Common Stock
2018-06-29$23.33/sh+393→ 5,143 total
Award
Revance Therapeutics, Inc.
Common Stock
2018-06-20+250→ 4,750 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2018-06-20+9,500→ 9,500 total

Companies

Revance Therapeutics, Inc.
Principal Financial Officer

Recent Filings

Address

C/O REVANCE THERAPEUTICS, INC 7555 GATEWAY BLVD

NEWARK, CA, 94560

View on SEC.gov